Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

104 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Modulation of NF-kappaB activity by exchange of dimers.
Saccani S, Pantano S, Natoli G. Saccani S, et al. Mol Cell. 2003 Jun;11(6):1563-74. doi: 10.1016/s1097-2765(03)00227-2. Mol Cell. 2003. PMID: 12820969
Two waves of nuclear factor kappaB recruitment to target promoters.
Saccani S, Pantano S, Natoli G. Saccani S, et al. J Exp Med. 2001 Jun 18;193(12):1351-9. doi: 10.1084/jem.193.12.1351. J Exp Med. 2001. PMID: 11413190 Free PMC article.
Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury.
Dieterle F, Perentes E, Cordier A, Roth DR, Verdes P, Grenet O, Pantano S, Moulin P, Wahl D, Mahl A, End P, Staedtler F, Legay F, Carl K, Laurie D, Chibout SD, Vonderscher J, Maurer G. Dieterle F, et al. Nat Biotechnol. 2010 May;28(5):463-9. doi: 10.1038/nbt.1622. Nat Biotechnol. 2010. PMID: 20458316
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Schuster SJ, et al. N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1. N Engl J Med. 2019. PMID: 30501490 Clinical Trial.
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.
Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, De Moerloose B, Nemecek ER, Bittencourt H, Hiramatsu H, Buechner J, Davies SM, Verneris MR, Nguyen K, Brogdon JL, Bitter H, Morrissey M, Pierog P, Pantano S, Engelman JA, Winckler W. Orlando EJ, et al. Nat Med. 2018 Oct;24(10):1504-1506. doi: 10.1038/s41591-018-0146-z. Epub 2018 Oct 1. Nat Med. 2018. PMID: 30275569
Vascular origin of vildagliptin-induced skin effects in Cynomolgus monkeys: pathomechanistic role of peripheral sympathetic system and neuropeptide Y.
Hoffmann P, Bentley P, Sahota P, Schoenfeld H, Martin L, Longo L, Spaet R, Moulin P, Pantano S, Dubost V, Lapadula D, Burkey B, Kaushik V, Zhou W, Hayes M, Flavahan N, Chibout SD, Busch S. Hoffmann P, et al. Toxicol Pathol. 2014 Jun;42(4):684-95. doi: 10.1177/0192623313516828. Epub 2014 Jan 20. Toxicol Pathol. 2014. PMID: 24448599
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. Soria JC, et al. Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24. Lancet. 2017. PMID: 28126333 Clinical Trial.
Eligible patients were assigned via interactive response technology to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m(2) or carboplatin AUC 5-6 plus pemetrexed 500 mg/m(2)] every 3 weeks for four cycles followed by maintenance pemetrexed); randomisat …
Eligible patients were assigned via interactive response technology to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin …
104 results
Jump to page